Logo

BforCure Obtains CE Mark for Portable PCR Thermocycler to Detect SARS-CoV-2

May 17, 2021 | staff reporter

NEW YORK ─ Paris-based point-of-care testing firm BforCure said on Monday that it has obtained CE marking for its Chronos Dx portable qPCR thermocycler, enabling its use for SARS-CoV-2 testing.

Chronos Dx uses a microfluidic thermal heating and cooling engine to rapidly cycle samples and enable multiplex qPCR testing in less than 15 minutes, BforCure said, adding it has placed its first portable thermocyclers for SARS-CoV-2 testing in France, including some at an undisclosed airport.

BforCure said it will retain Chronos Dx as an open platform to accommodate third party test kits for both in vitro diagnostic and research use, and it intends to develop additional tests in the near future.

Filed under

Point-of-Care Testing
Infectious Disease
PCR
Molecular Diagnostics
COVID-19
Europe
qPCR
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.